Immatics Enterprise Value Multiple from 2010 to 2025

IMTXW Stock  USD 0.02  0  6.98%   
Immatics Biotechnologies Enterprise Value Multiple yearly trend continues to be fairly stable with very little volatility. Enterprise Value Multiple will likely drop to -6 in 2025. During the period from 2010 to 2025, Immatics Biotechnologies Enterprise Value Multiple regression line of quarterly data had r-squared of  0.50 and coefficient of variation of (63.13). View All Fundamentals
 
Enterprise Value Multiple  
First Reported
2010-12-31
Previous Quarter
(5.71)
Current Value
(6.00)
Quarterly Volatility
7.04646742
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immatics Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics Biotechnologies' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 15.7 M or Interest Income of 16.7 M, as well as many indicators such as Price To Sales Ratio of 15.53, Dividend Yield of 0.0 or PTB Ratio of 3.22. Immatics financial statements analysis is a perfect complement when working with Immatics Biotechnologies Valuation or Volatility modules.
  
Check out the analysis of Immatics Biotechnologies Correlation against competitors.

Latest Immatics Biotechnologies' Enterprise Value Multiple Growth Pattern

Below is the plot of the Enterprise Value Multiple of immatics biotechnologies GmbH over the last few years. It is Immatics Biotechnologies' Enterprise Value Multiple historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Multiple10 Years Trend
Slightly volatile
   Enterprise Value Multiple   
       Timeline  

Immatics Enterprise Value Multiple Regression Statistics

Arithmetic Mean(11.16)
Coefficient Of Variation(63.13)
Mean Deviation5.79
Median(15.70)
Standard Deviation7.05
Sample Variance49.65
Range24.826
R-Value0.71
Mean Square Error26.68
R-Squared0.50
Significance0
Slope1.05
Total Sum of Squares744.79

Immatics Enterprise Value Multiple History

2025 -6.0
2024 -5.71
2023 -6.35
2022 8.25
2021 -7.43
2020 -3.45
2019 -16.58

About Immatics Biotechnologies Financial Statements

Immatics Biotechnologies investors use historical fundamental indicators, such as Immatics Biotechnologies' Enterprise Value Multiple, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immatics Biotechnologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Multiple(5.71)(6.00)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immatics Stock Analysis

When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.